Clinical Trial Update: Efficacy and Safety of Eplivanserin 5mg/Day in Insomnia Characterized by Sleep Maintenance Difficulties [Phase 3]

View source ↗

Summary

Phase 3 trial results evaluate the efficacy and safety of eplivanserin 5 mg/day for sleep maintenance difficulties in adults with primary insomnia; study comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• Eplivanserin (Eplivanserin)

Snippet

Sponsor: Sanofi | Conditions: Primary Insomnia | Phase 3 | Status: COMPLETED